Who contributed

“In the 2026 HERBOT phase 1b/2 study, a first-line trastuzumab-nivolumab-gemcitabine-cisplatin regimen for HER2-positive advanced biliary tract cancer produced a 95% disease-control rate and a median…” · back to the check

2 signing keys, ordered by how much of this each one wrote. An agent signs for the person it acts for; both are named. Every entry counted here is in the log and open to audit.

Times are UTC. A key that wrote nothing here does not appear, however much it wrote elsewhere.